newcleo plc Reports First Half 2026 Financial and Operational Results
First Half 2026 and Subsequent Commercial and Operational Highlights
- Completed business combination with NewHold Investment Corp III (“SPAC”) on
September 21, 2026 (the “Business Combination”); newcleo’s ordinary shares and warrants commenced trading on the Nasdaq Global Select Market onSeptember 22, 2026 under the symbols “NWCL” and “NWCLW,” respectively - The Business Combination generated gross proceeds of approximately
$247 million , consisting of approximately$31 million released from the SPAC’s trust account and$216 million from the PIPE financing - Raised approximately
$18 .7 million in additional financing unrelated to the Business Combination sinceMay 2026 , bringing total funds raised since newcleo’s founding to over$1 billion - Installed the main vessel and turbine for its PRECURSOR non-nuclear 10 MWt demonstration reactor at the
ENEA Brasimone Research Center outsideBologna, Italy ; completion of construction for PRECURSOR is expected by the end of 2026, with at-scale validation of systems to commence thereafter - In partnership with Oklo, selected by the
U.S. Department of Energy for advanced negotiations under the Surplus Plutonium Utilization Program - Submitted Regulatory Engagement Plans to the
U.S. Nuclear Regulatory Commission for the Company’s LFR-AS-200 lead-cooled fast reactor and its plannedU.S . mixed-oxide (MOX) fuel manufacturing facility - Received notice of an overall opinion of satisfactory compliance from the
French Nuclear Safety and Radiation Protection Authority for the proposed safety features for the Company’s planned MOX fuel manufacturing facility inFrance - Announced the acquisition, subject to customary closing conditions, of Bonifait Pesage, a French manufacturer of nuclear-grade scales and precision industrial weighing equipment, augmenting the Company’s vertically integrated capabilities
- Announced the appointment of
Jeffrey Lyash , a nuclear industry veteran and former head of theTennessee Valley Authority , as Chairman of the Board of Directors - Announced the appointment of
William D. Magwood as Vice-Chairman of newcleo’s Board of Directors, effectiveJanuary 1, 2027 - Announced the hiring of
Dustin Greenwood as Vice President ofU.S . Operations andTravis Chapman as Director ofU.S . Regulatory Affairs and Licensing, strengthening the Company’s growingU.S . team - Announced a partnership with SHINE to assess and jointly pursue opportunities relating to nuclear fuel recycling in the
United States andEuropean Union - On
September 10, 2026 , newcleo held an Analyst and Investor Day, a recording of which is available on newcleo’s website
First Half 2026 Financial Highlights
- Generated Revenue from Products and Services of approximately €19.4 million, an increase of approximately 46% over First Half 2025
- Reported Net Loss of approximately €82.0 million, an increase of approximately 10% over First Half 2025
- Reported Tangible Capital Expenditures of €25.3 million, an increase of 37% over First Half 2025
- Reported Selling, General & Administrative expenses of €59.2 million, an approximately 21% increase over First Half 2025
- Cash & Cash Equivalents as of
June 30, 2026 stood at €66.5 million - Total ordinary shares outstanding as of the closing date of the Business Combination stood at 281,534,950
- As of
September 30, 2026 , preliminary, unaudited Cash & Cash Equivalents for the Company stood at approximately €233 million
“Becoming a public company is a defining milestone for newcleo, and I want to thank every member of our team for the work that brought us to this point and to reporting our first results as a public company,” said
“Importantly, newcleo is moving quickly down the path to both technical validation and regulatory approval for our facilities. The installation of the main vessel for PRECURSOR, our 10 MWt non-nuclear demonstration reactor at Brasimone, is a development milestone for the LFR technology ahead of planned commercial deployment. Completion of construction for PRECURSOR, which is expected by the end of 2026, and beginning the process of reactor system validation, are the next critical steps in qualifying the technology that will lead to the deployment of our LFR-200 reactor.
“In parallel, pre-licensing for our reactor and MOX fuel facilities in
Commercial & Operational Events
On
On
On
Also subsequent to the first half, newcleo progressed work on the PRECURSOR non-nuclear demonstration reactor with the installation of the main vessel and turbine at ENEA’s Brasimone facility located outside of
“In the first half of 2026, newcleo continued moving our operations forward, continuing to convert planning into reality,” said
Regulatory Progress
Subsequent to the end of the first half, on
On
Hiring of Key Personnel
On
On
On
First Half Financial Summary
| (Amounts in thousands) | For the Six Months Ended | |||||
| Revenue from Products and Services | € | 19,429 | € | 13,347 | ||
| Gross Profit | 6,130 | 4,154 | ||||
| Other Income | 6,554 | 4,763 | ||||
| Net Loss | 81,981 | 74,293 | ||||
| Capital Expenditures | 26,970 | 19,000 | ||||
| Cash & Cash Equivalents (end of period) | 66,540 | 131,896 | ||||
Revenue from Products and Services increased by approximately €6.1 million, or approximately 46%, for the six months ended
Other Income increased by approximately €1.8 million, or 38%, for the six months ended
Gross Profit increased by approximately €2.0 million, or 48%, for the six months ended
Net loss increased by approximately €7.7 million, or 10%, for the six months ended
Tangible capital expenditures were approximately €25.3 million for the six months ended
Selling, General & Administrative expenses were €59.2 million for the six months ended
The Company had Cash & Cash Equivalents available of €66.5 million as of
About newcleo
newcleo is an innovative nuclear technology company developing advanced modular reactors and nuclear fuel designed to deliver clean, safe and sustainable energy at competitive costs. newcleo's technology combines lead-cooled fast reactors with fuel manufactured from recycled nuclear materials, with the aim of providing abundant and reliable electricity and heat to industrial users while enabling the closure of the nuclear fuel cycle. newcleo brings together more than 900 highly skilled employees across Europe and the United States, spanning reactor and fuel design, engineering, and manufacturing. Through a vertically integrated supply chain and a growing network of strategic partnerships, newcleo is working to turn proven scientific and engineering solutions into deployable nuclear energy assets. For more information visit http://www.newcleo.com
Contacts
For Investors and Media:
newcleo@icrinc.com
media@newcleo.com
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the U.S. federal securities laws. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding newcleo's development and commercialization of its lead-cooled fast reactor technology, mixed-oxide fuel capabilities and related products and services; the expected timing, cost, performance and benefits of newcleo's demonstration projects, fuel facilities, reactor deployments and licensing activities; newcleo's ability to execute its business strategy, develop its technology, obtain required regulatory approvals, permits and licenses, enter into commercial arrangements, achieve its market opportunity and positioning and support the growth of advanced nuclear energy; newcleo's expectations regarding strategic partnerships, customer demand, project pipeline, revenue streams, capital expenditures and financing needs; and other statements regarding management's intentions, beliefs, or expectations with respect to newcleo's future performance, are forward-looking statements. Forward-looking statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “develop,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on newcleo's current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. You should carefully consider the foregoing factors and the other risks and uncertainties described in other documents filed from time to time by newcleo with the SEC. Additional risks and uncertainties not currently known or that are currently deemed immaterial may also cause actual results to differ materially from those expressed or implied by such forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and newcleo does not assume any obligation or intend to update or revise these forward-looking statements, each of which is made only as of the date of this press release.
| Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income (Unaudited) | |||
| For the six months ended |
For the six months ended |
||
| 2026 | 2025 | ||
| (in thousands of euros unless otherwise stated) | Convenience translation into US dollars* | ||
| Revenue from Products and Services | 19,429 | 13,347 | 22,149 |
| Cost of sales | (13,299) | (9,193) | (15,161) |
| Gross profit | 6,130 | 4,154 | 6,988 |
| Other income | 6,554 | 4,763 | 7,472 |
| Research and development expenses | (34,629) | (35,450) | (39,477) |
| Selling, General and Administrative expenses | (59,170) | (48,932) | (67,454) |
| Operating loss | (81,115) | (75,465) | (92,471) |
| Loss on disposal of assets | (9) | (3) | (10) |
| Finance income | 353 | 1,581 | 402 |
| Finance costs | (1,448) | (991) | (1,650) |
| Share of loss of associates | (83) | - | (95) |
| Loss before income tax | (82,302) | (74,878) | (93,824) |
| Income tax benefit | 321 | 585 | 366 |
| Net loss | (81,981) | (74,293) | (93,458) |
| Other comprehensive income (loss) | |||
| Items that may be subsequently reclassified to profit or loss | |||
| Currency translation differences | 198 | (144) | 226 |
| Other comprehensive income (loss), net of tax | 198 | (144) | 226 |
| Total comprehensive loss | (81,783) | (74,437) | (93,232) |
| Net loss attributable to: | |||
| Owners of newcleo plc | (81,981) | (74,293) | (93,458) |
| Non-controlling interest | - | - | - |
| Total comprehensive loss attributable to: | |||
| Owners of newcleo plc | (81,783) | (74,437) | (93,232) |
| Non-controlling interest | - | - | - |
| Net loss per share for loss attributable to the ordinary equity holders: | |||
| Basic and diluted loss per share | (0.16) | (0.16) | (0.18) |
*Convenience translation into US dollars in thousands (exchange rate as at
Note: EPS for the period ended
| Condensed Consolidated Statements of Financial Position (Unaudited) |
|||
| (in thousands of euros unless otherwise stated) |
Convenience translation into US dollars* | ||
| ASSETS | |||
| NON-CURRENT ASSETS | |||
| 37,281 | 37,281 | 42,500 | |
| Intangible assets, net | 42,760 | 43,054 | 48,746 |
| Property, plant and equipment, net | 115,999 | 93,436 | 132,239 |
| Right-of-use asset | 17,665 | 18,521 | 20,138 |
| Investments | 76 | 75 | 87 |
| Investments in associates | 31,553 | 31,635 | 35,970 |
| Other long-term receivables | 34,871 | 35,207 | 39,753 |
| Deferred tax assets | 3,059 | 2,176 | 3,487 |
| TOTAL NON-CURRENT ASSETS | 283,264 | 261,385 | 322,920 |
| CURRENT ASSETS | |||
| Inventories | 4,843 | 5,057 | 5,521 |
| Short-term investments | 2,335 | 2,291 | 2,662 |
| Trade receivable, contract and other assets, net | 77,768 | 62,314 | 88,656 |
| Cash and cash equivalents | 66,540 | 105,270 | 75,856 |
| TOTAL CURRENT ASSETS | 151,486 | 174,932 | 172,695 |
| TOTAL ASSETS | 434,750 | 436,317 | 495,615 |
| NON-CURRENT LIABILITIES | |||
| Provisions | 4,094 | 4,170 | 4,667 |
| Other liabilities | 8,932 | 9,305 | 10,182 |
| Lease liabilities | 14,667 | 15,537 | 16,720 |
| Borrowings | 15,929 | 16,306 | 18,159 |
| Deferred tax liabilities | 4,430 | 4,244 | 5,050 |
| TOTAL NON-CURRENT LIABILITIES | 48,052 | 49,562 | 54,778 |
| CURRENT LIABILITIES | |||
| Provisions | 378 | 186 | 431 |
| Trade and other payables | 60,055 | 83,808 | 68,463 |
| Lease liabilities | 3,545 | 3,250 | 4,041 |
| Borrowings | 2,497 | 2,583 | 2,847 |
| TOTAL CURRENT LIABILITIES | 66,475 | 89,827 | 75,782 |
| TOTAL LIABILITIES | 114,527 | 139,389 | 130,560 |
| EQUITY | |||
| Share capital | 5,046 | 4,739 | 5,752 |
| Share premium | 23,378 | 562,904 | 26,652 |
| Other reserves | 57,067 | 51,383 | 65,057 |
| Retained earnings (accumulated deficits) | 234,695 | (324,123) | 267,552 |
| Equity attributable to owners of newcleo plc | 320,186 | 294,903 | 365,013 |
| Non-controlling interests | 37 | 2,025 | 42 |
| TOTAL EQUITY | 320,223 | 296,928 | 365,055 |
| TOTAL EQUITY AND LIABILITIES | 434,750 | 436,317 | 495,615 |
*Convenience translation into US dollars in thousands (exchange rate as at
| Condensed Consolidated Cash Flow Statement (Unaudited) | |||
| For the six months ended |
For the six months ended |
||
| 2026 | 2025 | ||
| (in thousands of euros) | Convenience translation into US$* | ||
| Cash flows from operating activities | |||
| Net loss | (81,981) | (74,293) | (93,458) |
| Adjustments to reconcile net loss to net cash flows: | |||
| Loss from associates | 83 | - | 95 |
| Finance income | (30) | (1,476) | (34) |
| Finance costs | 1,131 | 830 | 1,289 |
| Income tax benefit | (321) | (585) | (366) |
| Depreciation of property, plant and equipment and right-of-use assets, amortization intangible assets and provisions | 8,286 | 7,397 | 9,446 |
| Share-based payment expense | 21,010 | 4,975 | 23,951 |
| Loss on disposals | 9 | 4 | 10 |
| Other revenues and expenses without effect on cash flow | 3 | 5 | 3 |
| Changes in working capital: | - | ||
| Decrease in inventory | 214 | 94 | 244 |
| (Increase) in trade receivables, contract and other assets | (15,217) | (6,781) | (17,347) |
| Increase (decrease) in trade and other payables | 13,077 | (2,428) | 14,908 |
| Income taxes received | 49 | 25 | 56 |
| Net cash flows used in operating activities | (53,687) | (72,233) | (61,203) |
| Cash flows from investing activities | |||
| Acquisition of intangible assets | (1,642) | (458) | (1,872) |
| Purchase of property, plant and equipment | (25,328) | (18,542) | (28,874) |
| Proceeds from maturities of short-term investments | - | 997 | - |
| Purchase of short-term investments | (41) | (160) | (47) |
| Interest received from short-term investments | 30 | 1,477 | 34 |
| Decrease (increase) in loans and deposits made | 4 | (2) | 5 |
| Proceeds from sale of tangible and intangible assets | 10 | 5 | 12 |
| Net cash flows used in investing activities | (26,967) | (16,683) | (30,742) |
| Cash flows from financing activities | |||
| Proceeds from issues of shares | 45,121 | - | 51,438 |
| Proceeds from issue of shares to non-controlling shareholders | - | 31,637 | - |
| Repayments of borrowings and lease liabilities | (2,129) | (2,535) | (2,427) |
| Interest expenses including interest on lease | (1,131) | (800) | (1,289) |
| Net cash flows from financing activities | 41,861 | 28,302 | 47,722 |
| Net decrease in cash and cash equivalents | (38,793) | (60,614) | (44,223) |
| Cash and cash equivalents at the beginning of the period | 105,270 | 192,714 | 120,008 |
| Effect of foreign exchange rate changes | 63 | (204) | 71 |
| Cash and cash equivalents at the end of the period | 66,540 | 131,896 | 75,856 |
*Convenience translation into US$ in thousands (exchange rate as at
